Last reviewed · How we verify
VBP15
At a glance
| Generic name | VBP15 |
|---|---|
| Sponsor | ReveraGen BioPharma, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT
- Expanded Access Protocol for Boys With Duchenne Muscular Dystrophy
- A Study on Safety and Effectiveness of Long-term Treatment With Vamorolone in Boys With Duchenne Muscular Dystrophy (PHASE4)
- Evaluation of Vamorolone CYP3A4 Induction on Midazolam (a Sensitive CYP 3A4 Substrate) Pharmacokinetics (PHASE1)
- A Study to Assess Vamorolone in Boys Ages 2 to <4 Years and 7 to <18 Years With Duchenne Muscular Dystrophy (DMD) (PHASE2)
- A Study to Assess Vamorolone in Becker Muscular Dystrophy (BMD) (PHASE2)
- Evaluation of Vamorolone Mineralocorticoid Receptor Antagonism in Healthy Subjects (PHASE1)
- A Study to Assess the Efficacy and Safety of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VBP15 CI brief — competitive landscape report
- VBP15 updates RSS · CI watch RSS
- ReveraGen BioPharma, Inc. portfolio CI